Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus

What Was Tested

Researchers studied GIP (Gastric Inhibitory Polypeptide) in this randomized controlled trial publication.

Who Took Part

The abstract describes 56 patients taking part.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this GIP (Gastric Inhibitory Polypeptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the patients nor the staff measuring them knew who was on GIP (Gastric Inhibitory Polypeptide), so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with GIP (Gastric Inhibitory Polypeptide) could be set against what happens without it.

Adverse events (AEs), vital signs, ECGs and routine laboratory variables were intensively monitored.

Drug concentrations, fasting glycaemic variables, 24-hour glucose profiles, glycated haemoglobin (HbA1c) and antibody formation were measured.

Several meal tolerance and gastric emptying tests were performed during the study.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Diabetes Mellitus, Type 2, Drugs, Investigational, Gastric Inhibitory Polypeptide, Glucagon-Like Peptide 1 and Hypoglycemic Agents.

The authors tagged it with the keywords NNC0090-2746, RG7697, RO6811135, dual GIP/GLP-1 agonist, safety and type 2 diabetes mellitus.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of GIP (Gastric Inhibitory Polypeptide) in 56 patients.

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2017 (Diabetes, obesity & metabolism), a journal based in England.

More context: the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.